Assessing liver fat changes in cancer patients undergoing chemotherapy
Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver
NA · Yunnan Cancer Hospital · NCT06735118
This study is testing a new scanning method to see how chemotherapy affects liver fat in cancer patients before and after treatment.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Yunnan Cancer Hospital (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Kunming, Yunnan) |
| Trial ID | NCT06735118 on ClinicalTrials.gov |
What this trial studies
This study aims to quantitatively evaluate changes in liver fat content in cancer patients before and after receiving neoadjuvant chemotherapy. It utilizes a novel deep learning-based mDixon Quant scanning technique that automates the segmentation and measurement of liver fat, improving accuracy and efficiency compared to traditional methods. By employing a threshold extraction method, the study seeks to provide a comprehensive assessment of liver fat fraction, which is crucial for understanding the impact of chemotherapy on liver health.
Who should consider this trial
Good fit: Ideal candidates for this study are cancer patients who have not been diagnosed with fatty liver and are undergoing neoadjuvant or adjuvant chemotherapy.
Not a fit: Patients with existing liver lesions or those who cannot undergo MRI due to contraindications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate monitoring of liver health in cancer patients undergoing chemotherapy, potentially improving treatment outcomes.
How similar studies have performed: While this approach is innovative, similar studies utilizing advanced imaging techniques for liver assessment have shown promise, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. CT/B ultrasound showed no fatty liver 2. No MRI contraindications, including pacemaker, stent, metal implant, or claustrophobia 3. Received neoadjuvant/adjuvant chemotherapy Exclusion Criteria: 1. Missing follow-up information 2. Liver lesions (metastases, hemangioma, etc.) 3. Poor image quality
Where this trial is running
Kunming, Yunnan
- Yunnan Cancer Hospital — Kunming, Yunnan, China (RECRUITING)
Study contacts
- Study coordinator: Lizhu Liu, Graduate
- Email: liulizhu2022@163.com
- Phone: 18287509587
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Non-Alcoholic Fatty Liver Disease